Editas Medicine (EDIT) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

EDIT Editas Medicine

Watchlist

1.440
-0.450-23.81%

Close Dec 13 16:00 ET

1.450
+0.010+0.69%

Post 20:01 ET

118.87MMarket Cap-0.57P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Morgan Stanley Maintains Editas Medicine(EDIT.US) With Hold Rating
Moomoo NewsDec 14 09:31 ET · Ratings
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $3
Moomoo NewsDec 14 08:00 ET · Ratings
Editas Medicine Price Target Lowered to $8 From $10 at Baird
Yahoo FinanceDec 14 07:01 ET
Editas Medicine Reshapes Future With In Vivo Focus Amid Major Workforce Cuts
Yahoo FinanceDec 13 13:26 ET
Editas Medicine Is Maintained at Sector Perform by RBC Capital
Dow JonesDec 13 12:38 ET · Ratings
RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $4
BenzingaDec 13 12:28 ET · Ratings

Comments

Broke Trader

Dec 12 15:08

Editas Medicine Inc - Expected Costs of $55 Million to $70 Million

$Editas Medicine (EDIT.US)$

Jaguar8

Dec 12 15:01

NEWS

$Editas Medicine (EDIT.US)$
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
Thursday, 12th December at 4:00 pm
• Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues:
◦ Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell...

Stock_Drift

Dec 9 14:23

$Editas Medicine (EDIT.US)$

Trytosaveabit

Oct 22 06:22

$Editas Medicine (EDIT.US)$ Editas Medicine Announced In Vivo Preclinical Proof Of Concept Data Of Hematopoietic Stem And Progenitor Cell Editing And Fetal Hemoglobin Induction In Humanized Mice Engrafted With Human Hematopoietic Stem Cells And Lacking Their Own Hematopoietic Cells
Benzinga· 2 mins ago
The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP...

Jaguar8

Oct 3 23:44

AH NEWS TODAY

$Editas Medicine (EDIT.US)$
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.
The deal includes up to 100% of future ann...

Heat List

Overall

No Data

Investment Theme

Gene Editing

Intraday-0.48%